Korro to Participate in Upcoming June Investor and Scientific Conferences
May 30 2024 - 4:01PM
Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members
of management will participate in the following upcoming investor
and scientific conferences:
Jefferies Global Healthcare
Conference Chief Executive Officer and President, Ram
Aiyar, Ph.D., will present on Thursday, June 6, 2024, at 2:00 p.m.
ET. Chief Financial Officer, Vineet Agarwal, will also be
participating at the conference.
2024 Alpha-1 Foundation
National ConferenceChief Medical Officer, Kemi Olugemo,
M.D., FAAN, will discuss Korro’s lead RNA editing oligonucleotide
candidate in a presentation titled, “KRRO-110, a RNA Editing
Modality for the Treatment of Alpha-1 Antitrypsin Deficiency” on
Saturday, June 8, 2024, at 11:20 a.m. ET.
5th
Annual RNA Editing SummitSenior Vice President
& Head of Platform, RNA Editing, Venkat Krishnamurthy, Ph.D.,
will participate in a roundtable discussion titled “Discussing
Strategies for Improved Longevity of Editing Therapeutics to
Achieve More Durable Effects” on Thursday, June 20, 2024. at 11:00
a.m. ET.
Dr. Krishnamurthy will also deliver a
presentation titled “Edit the Message: Rewrite the Future” on June
20 at 1:30 p.m. ET. This presentation will provide an update on
Korro’s proprietary OPERA platform (Oligonucleotide Promoted
Editing of RNA) and its progress towards the clinic.
A live webcast of the Jefferies presentation can
be accessed on the “Events & Presentations” page in the
Investor section of Korro’s website at www.korrobio.com. Following
the presentation, a replay of the event will be available for 30
days.
About Korro Korro is a
biopharmaceutical company focused on developing a new class of
genetic medicines for both rare and highly prevalent diseases using
its proprietary RNA editing platform. Korro is generating a
portfolio of differentiated programs that are designed to harness
the body’s natural RNA editing process to effect a precise yet
transient single base edit. By editing RNA instead of DNA, Korro is
expanding the reach of genetic medicines by delivering additional
precision and tunability, which has the potential for increased
specificity and improved long-term tolerability. Using an
oligonucleotide-based approach, Korro expects to bring its
medicines to patients by leveraging its proprietary platform with
precedented delivery modalities, manufacturing know-how, and
established regulatory pathways of approved oligonucleotide drugs.
Korro is based in Cambridge, Massachusetts. For more information,
visit korrobio.com.
Korro Contact Information
InvestorsIR@korrobio.com
MediaGlenn Silver FINN
Partners Glenn.silver@finnpartners.com
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
From Oct 2023 to Oct 2024